Prasinezumab  (Synonyms: PRX 002; RG 7935; RO 7046015)

Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

Prasinezumab against an epitope in the carboxyl terminus of human α-synuclein. Prasinezumab binds to human aggregated α-synuclein with a high affinity and avidity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

6622  [NCBI]

P37840

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.26 kDa

1960462-19-4

Liquid

Colorless to light yellow

[Prasinezumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized SNCA Protein, Human (HY-P70577) can bind Prasinezumab. The EC₅₀ for this effect is 11.77 ng/mL.
• 
  Flow cytometric analysis of 1X10⁶ Hela cells with Prasinezumab (HY-P99405, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Gennaro Pagano, et al. A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. Front Neurol. 2021 Oct 1;12:705407.  [Content Brief]